

**RECEIVED  
CENTRAL FAX CENTER****DEC 01 2006**

**MYERS BIGEL SIBLEY & SAJOVEC, P.A.**  
**Patent Attorneys**  
**4140 Parklake Avenue, Suite 600, Raleigh, NC 27612**  
**or**  
**P.O. Box 37428**  
**Raleigh, NC 27627**  
**919-854-1400**  
**Facsimile 919-854-1401**

**FACSIMILE TRANSMISSION  
COVER SHEET**

**CERTIFICATION OF FACSIMILE TRANSMISSION  
UNDER 37 CFR § 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the U. S. Patent and Trademark Office via the central facsimile number 571-273-8300 on December 1, 2006 and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O., Box 1450, Alexandria, VA 22313-1450.

  
Amelia Tauchen

**Attorney Docket No. 3477-112**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re: Wu et al.**  
**Application No.: 10/538,951**  
**Filed: March 28, 2006**

**Confirmation No. 5581**  
**Group Art Unit: 1654**  
**Examiner: Hemant Khanna**

**Title: ACE INHIBITORY PEPTIDES FROM PLANT MATERIALS**

**ATTACHED:**

**Faxcover**  
**Response**  
**TOTAL**

**1 page**  
**2 pages**  
**3 Pages**

**Confidentiality Note**

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby prohibited. If you have received this telecopy in error, please immediately notify us by telephone and return the original message to us at the address above via the United States Postal Service. **THANK YOU.**

DEC 01 2006

Attorney Docket No. 3477-112

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Wu et al.

Application No.: 10/538,951

Filed: March 28, 2006

Title: *ACE INHIBITORY PEPTIDES FROM PLANT MATERIALS*

Confirmation No. 5581

Group Art Unit: 1654

Examiner: Hemant Khanna

Date: December 1, 2006

Mail Stop Amendment  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

Claims 1-41, 43 and 44 are pending in this application. In the outstanding Restriction Requirement dated November 1, 2006, claims 1-41, 43 and 44 were restricted into three groups. In response to the Restriction Requirement, Applicants elect the claims of Group I (claims 1-30, drawn to a process for preparing an angiotensin converting enzyme inhibitory peptide-containing hydrolysate) with traverse.

The traversal of the restriction is on the basis that claims 31, 34-39 of Group II and claims 43 and 44 of Group III are dependent on claim 1 and therefore have unity of invention. It is therefore respectfully requested that the outstanding Restriction Requirement be withdrawn, and that at least claims 1-31, 34-39, 43 and 44 be examined concurrently.

The Office Action further requires that a species be elected for the purposes of search and examination. The Applicants elect the enzyme Alcalase 2.4L. This election of species is made without traverse to the extent it is understood that, upon the finding of an allowable species, examination will continue with the non-elected species until all species have been examined or a non-allowable species is identified.